LOX-1 is a novel marker for peripheral artery disease in patients with type 2 diabetes

被引：35

作者：

Fukui, Michiaki ^{[1
]}

Tanaka, Muhei ^{[1
]}

Senmaru, Takafumi ^{[1
]}

Nakanishi, Mamoru ^{[2
]}

Mukai, Jun ^{[3
]}

Ohki, Makoto ^{[3
]}

Asano, Mai ^{[1
]}

Yamazaki, Masahiro ^{[1
]}

Hasegawa, Goji ^{[1
]}

Nakamura, Naoto ^{[1
]}

机构：

[1] Kyoto Prefectural Univ Med, Dept Endocrinol & Metab, Grad Sch Med Sci, Kamigyo Ku, Kyoto 6028566, Japan

[2] Kyoto Prefectural Univ Med, Kyoto 6028566, Japan

[3] Biomarker Sci Co Ltd, Kyoto, Japan

来源：

METABOLISM-CLINICAL AND EXPERIMENTAL | 2013年 / 62卷 / 07期

关键词：

Ankle-brachial index; Cardiovascular disease; Oxidized low-density lipoprotein; LOW-DENSITY-LIPOPROTEIN; OXIDIZED LDL RECEPTOR-1; ENDOTHELIAL RECEPTOR; EXPRESSION; LIGAND;

D O I：

10.1016/j.metabol.2013.01.018

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective. The aim of this study was to investigate whether serum soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1), which mediates initiation and progression of atherosclerosis in endothelial cells, could be a novel marker for peripheral artery disease (PAD) in patients with type 2 diabetes. Methods. We evaluated relationships of serum sLOX-1 to ankle-brachial index (ABI) and examined the association of serum sLOX-1 with PAD in 410 patients with type 2 diabetes. Results. Serum sLOX-1 was inversely correlated with ABI (r=-0.197, P<0.0001). Stepwise regression analysis demonstrated that serum sLOX-1 (beta=-0.168, F=5.571, P<0.05) was independently associated with ABI, and multiple logistic regression analysis demonstrated that serum sLOX-1 (16.254(1.237-213.651), P=0.0339) was independently associated with PAD. Conclusions. Serum sLOX-1 is associated with ABI and it could be a novel marker for PAD in patients with type 2 diabetes. (C) 2013 Elsevier Inc. All rights reserved.

引用

页码：935 / 938

页数：4

共 19 条

[1] Induction of lectin-like oxidized LDL receptor by oxidized LDL and lysophosphatidylcholine in cultured endothelial cells [J].